Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
uniQure’s gene-therapy filings aren’t light reading. Between pages of clinical data, royalty accounting for Hemgenix and detailed manufacturing disclosures, even seasoned biotech investors can miss what moves the stock. If you’ve ever typed “How do I read uniQure’s 10-K?” or searched for “uniQure insider trading Form 4 transactions,” you know the challenge.
Stock Titan turns those 200-page documents into clear, actionable insights. Our AI-powered summaries explain complex sections of the uniQure annual report 10-K simplified, flag trial milestones in each uniQure quarterly earnings report 10-Q filing, and translate every uniQure 8-K material events explained into plain English within minutes of EDGAR release. Need management sentiment? Real-time alerts surface uniQure executive stock transactions Form 4 so you can track buying or selling before the market reacts. From cash-burn analysis to partnership revenue recognition, the platform answers the natural question, “What does uniQure report in their SEC filings?”
You’ll also find one-click access to the company’s proxy statement for executive compensation, shelf registrations that fund future trials, and historical uniQure Form 4 insider transactions real-time feeds. Whether you’re comparing quarter-over-quarter pipeline spend, monitoring dilution risk, or simply looking for a concise uniQure earnings report filing analysis, Stock Titan’s expert layers and AI context keep you ahead without wading through jargon. Understanding uniQure SEC documents with AI means informed decisions, faster.
uniQure N.V. (QURE) has filed a Form S-8 with the SEC to register an additional 2,400,000 ordinary shares (par value €0.05) for issuance under its Amended and Restated 2014 Share Incentive Plan. The increase was approved by the board on 15 Apr 2025 and by shareholders on 11 Jun 2025. These shares are in addition to roughly 15.9 million ordinary shares previously registered on six earlier S-8 filings covering the same plan. No financial statements or earnings data are included; the filing is purely administrative, enabling future equity-based compensation grants. Key exhibits include the Dutch legal opinion (Ex. 5.1), auditor consent (Ex. 23.2) and the full 2014 Plan (Ex. 99.1). While the move supports employee retention and alignment, it also represents potential shareholder dilution once the options or awards are exercised.
Director Jeremy P. Springhorn of uniQure reported a sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Springhorn retains direct ownership of 37,694 shares.
Key details of the transaction:
- The sale was non-discretionary, executed automatically to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was conducted under automatic sale instructions included in the Restricted Share Unit Agreement
- The Form 4 was filed by Christian Klemt as attorney-in-fact
This transaction appears to be a routine share sale for tax purposes rather than a strategic investment decision by the director.
uniQure Director Leonard E. Post reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, according to automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Post continues to directly own 29,937 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Total Transaction Value: Approximately $30,518
- Ownership Form: Direct
- Filing was signed by Christian Klemt as Attorney-in-Fact
Director Jack Kaye of uniQure reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Kaye retains direct ownership of 20,439 shares.
Key transaction details:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- The sale was non-discretionary and not a voluntary trade by the director
- Form was filed through an attorney-in-fact on June 24, 2025
uniQure director Rachelle Suzanne Jacques reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50).
Key details of the transaction:
- The sale was automatically executed to cover estimated withholding taxes upon vesting of restricted share units
- Transaction was made according to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Jacques continues to hold 28,346 ordinary shares directly
- The filing was signed by Christian Klemt as attorney-in-fact on June 24, 2025
This transaction represents a routine tax-related share sale rather than a discretionary trading decision by the insider.
uniQure Director Robert Gut reported a non-discretionary sale of 3,336 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed automatically to cover estimated tax withholdings following the vesting of restricted share units.
Following the reported transaction, Gut maintains direct beneficial ownership of 56,879 ordinary shares. The sale was conducted pursuant to automatic sale instructions included in the Restricted Share Unit Agreement and was not a discretionary trade by the reporting person.
- Transaction type: Non-discretionary sale (S)
- Purpose: Tax withholding coverage
- Execution: Automatic upon RSU vesting
- Filing relationship: Director
Director Madhavan Balachandran of uniQure reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated tax withholdings following the vesting of restricted share units, in accordance with automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Balachandran continues to hold 37,697 ordinary shares directly. The sale was conducted through a pre-arranged automatic selling plan and was not a discretionary trade by the reporting person.
- Transaction Code: S (Sale)
- Ownership Form: Direct (D)
- Transaction was executed pursuant to automatic sale instructions
- Filing was signed by Christian Klemt as Attorney-in-Fact on June 24, 2025
uniQure Director David D. Meek reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, in accordance with automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Meek continues to directly own 34,190 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Transaction Code: S
- Ownership Type: Direct
- Role: Director
uniQure N.V. Chief Legal Officer Jeannette Potts reported a non-discretionary sale of 4,670 ordinary shares on June 16, 2025, at a weighted average price of $15.14 per share (range: $15.00-$15.22).
Key details of the transaction:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Potts directly owns 115,073 ordinary shares
- The sale was non-discretionary and not a voluntary trade by the insider
This Form 4 filing was signed by Christian Klemt as Attorney-in-Fact on June 20, 2025, and demonstrates standard tax-related share disposition following equity compensation vesting.
FAQ
What is the current stock price of Uniqure (QURE)?
What is the market cap of Uniqure (QURE)?
What is uniQure's core business focus?
Which diseases are targeted by uniQure's therapies?
How does uniQure generate revenue?
What role does technology play in uniQure's approach?
Who are uniQure's key strategic partners?
How is uniQure positioned within the competitive landscape?
What is the significance of a modular technology platform for uniQure?
What are common challenges faced by companies in the gene therapy industry?
